Journal ArticleDOI
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Reads0
Chats0
About:
This article is published in Yearbook of Oncology.The article was published on 2010-01-01. It has received 850 citations till now. The article focuses on the topics: Dasatinib & Imatinib.read more
Citations
More filters
Journal ArticleDOI
Practical Monitoring of Chronic Myelogenous Leukemia: When to Change Treatment
Giuseppe Saglio,Carmen Fava +1 more
TL;DR: Experts of the European LeukemiaNet and NCCN have indicated what degrees of hematologic, cytogenetic, and molecular responses should be expected at definite time points for patients with CML to have the highest probability of experiencing the final optimal response.
Journal ArticleDOI
Tyrosine kinase inhibitors and interferon
Maria Dimou,P Panayiotidis +1 more
TL;DR: The current challenge is the combined use of second generation TKIs with pegylated –IFN, in order to minimize failures to therapy and increase the number of CML patients with deep molecular responses, who may be able to discontinue lifelong treatment.
Journal ArticleDOI
Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells
Michael Gutknecht,Julian Geiger,Simone Joas,Daniela Dörfel,Helmut R. Salih,Martin Müller,Frank Grünebach,Susanne M Rittig +7 more
TL;DR: This work inadvertently missed to include research funding organisations that supported this work, and missing research funding was supplemented in the acknowledgements.
Journal ArticleDOI
Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia
TL;DR: Current available data on possibility of holding TKI therapy in patients in deep remission [treatment-free remission (TFR)] and safety of this approach are reviewed and there is growing body of evidence that some CML patients who have achieved stable deep molecular response can safely stop TKI.
Journal ArticleDOI
Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.
Michael J Webb,C.L. Barrett,Christel Pretorius,Magdalena F. P. C. van Jaarsveld,Vernon J. Louw +4 more
TL;DR: The experience of a single centre in the management of 10 patients infected with the human immunodeficiency virus co-morbid for HIV is described, including demographic information, disease characteristics and response to therapy.
References
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.